Asciminib Hydrochloride

CHEMBL4297220 Phase 4 Onaylandı Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

486.3 g/mol

LogP

—

Phase

4

The hydrochloride salt of asciminib that blocks the BCR-ABL1 oncoprotein through a novel allosteric mechanism, offering an option for patients with CML whose leukemia has resisted other tyrosine kinase inhibitors.

Moleküler Ağırlık

486,3000 g/mol

TPSA

103,00 Å²

Etki Mekanizması

Selectively inhibits specific receptor tyrosine kinases involved in tumor cell proliferation, angiogenesis, and survival signaling. By blocking ATP binding to the kinase domain, it prevents phosphorylation cascades that drive cancer cell growth.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mekanizma

Selectively inhibits specific receptor tyrosine kinases involved in tumor cell proliferation, angiogenesis, and survival signaling. By blocking ATP binding to the kinase domain, it prevents phosphorylation cascades that drive cancer …

2D Yapı

SVG PNG

Cite this structure

Embed this structure

SMILES

Cl.O=C(Nc1ccc(OC(F)(F)Cl)cc1)c1cnc(N2CC[C@@H](O)C2)c(-c2cc[nH]n2)c1

InChI

InChI=1S/C20H18ClF2N5O3.ClH/c21-20(22,23)31-15-3-1-13(2-4-15)26-19(30)12-9-16(17-5-7-25-27-17)18(24-10-12)28-8-6-14(29)11-28;/h1-5,7,9-10,14,29H,6,8,11H2,(H,25,27)(H,26,30);1H/t14-;/m1./s1

Molecular Formula

C20H19Cl2F2N5O3

HBD / HBA

4 / 8

Döndürülebilir Bağlar

6

Ağır Atomlar

32

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Sıkça Sorulan Sorular

The hydrochloride salt of asciminib that blocks the BCR-ABL1 oncoprotein through a novel allosteric mechanism, offering an option for patients with CML whose leukemia has resisted other tyrosine kinase inhibitors.

Selectively inhibits specific receptor tyrosine kinases involved in tumor cell proliferation, angiogenesis, and survival signaling. By blocking ATP binding to the kinase domain, it prevents phosphorylation cascades that drive cancer cell growth.

Yes, Asciminib Hydrochloride is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL4297220. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 133082086. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Hasta dostu bilgi mi arıyorsunuz?

Asciminib Hydrochloride PillFYI'da

Yapı

Hızlı Veriler

Formül: C20H19Cl2F2N5O3

Dış Bağlantılar

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Tıbbi Sorumluluk Reddi

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.